ERBB2 and breast cancer: The CAMBRIA trials are ongoing randomized, open-label studies designed to evaluate the efficacy and safety of camizestrant, a selective estrogen receptor degrader (SERD), versus standard endocrine therapy in patients with ER-positive, HER2-negative early BC [40].